1 | maintenance | 11,053 |
2 | continuation | 1,415 |
3 | weight-maintenance | 37 |
4 | st-analysis | 17 |
5 | heparin-free | 16 |
6 | 52-weeks | 11 |
7 | maintainance | 11 |
8 | hhm | 10 |
9 | 0.8-mg | 7 |
10 | 14-weeks | 7 |
11 | 20-mg/day | 6 |
12 | 750mg/kg | 6 |
13 | continuation/maintenance | 6 |
14 | cs-137 | 6 |
15 | ldb-cpr | 6 |
16 | 70-mg/d | 5 |
17 | cotransplantation | 5 |
18 | post-ban | 5 |
19 | every-4-weeks | 4 |
20 | induction/maintenance | 4 |
21 | post-fa | 4 |
22 | recidives | 4 |
23 | suppressibility | 4 |
24 | 400-mg-bid | 3 |
25 | 48iu | 3 |
26 | concealer | 3 |
27 | cytosorb | 3 |
28 | day-15 | 3 |
29 | fev1-decline | 3 |
30 | hepatic-arterial | 3 |
31 | induction/stabilization | 3 |
32 | interferon-alpha/ribavirin | 3 |
33 | maintenance/regain | 3 |
34 | mono-administration | 3 |
35 | pseudorotation | 3 |
36 | tumor-inhibiting | 3 |
37 | 4-g/day | 2 |
38 | 6-mg/kg | 2 |
39 | diethylether | 2 |
40 | end-of-maintenance | 2 |
41 | exothermicities | 2 |
42 | flukicide | 2 |
43 | ifn-alpha2 | 2 |
44 | osb4 | 2 |
45 | phasing-out | 2 |
46 | pre-control | 2 |
47 | precarcinogenic | 2 |
48 | triers | 2 |
49 | ve-100 | 2 |
50 | » | 2 |
51 | 28.4-g | 1 |
52 | azythromicin | 1 |
53 | bronchodialator | 1 |
54 | complications.both | 1 |
55 | examination/installation | 1 |
56 | follow-up.whether | 1 |
57 | group-290 | 1 |
58 | highflux | 1 |
59 | improvement.the | 1 |
60 | mini-prophylactic | 1 |
61 | o3pufa-enriched | 1 |
62 | pivoxil/kg/day | 1 |
63 | regimen.this | 1 |
64 | severity/previous | 1 |
65 | tsh-suppressing | 1 |
1 | 0.8-mg | 7 |
2 | 14-weeks | 7 |
3 | 20-mg/day | 6 |
4 | 28.4-g | 1 |
5 | 4-g/day | 2 |
6 | 400-mg-bid | 3 |
7 | 48iu | 3 |
8 | 52-weeks | 11 |
9 | 6-mg/kg | 2 |
10 | 70-mg/d | 5 |
11 | 750mg/kg | 6 |
12 | azythromicin | 1 |
13 | bronchodialator | 1 |
14 | complications.both | 1 |
15 | concealer | 3 |
16 | continuation | 1,415 |
17 | continuation/maintenance | 6 |
18 | cotransplantation | 5 |
19 | cs-137 | 6 |
20 | cytosorb | 3 |
21 | day-15 | 3 |
22 | diethylether | 2 |
23 | end-of-maintenance | 2 |
24 | every-4-weeks | 4 |
25 | examination/installation | 1 |
26 | exothermicities | 2 |
27 | fev1-decline | 3 |
28 | flukicide | 2 |
29 | follow-up.whether | 1 |
30 | group-290 | 1 |
31 | heparin-free | 16 |
32 | hepatic-arterial | 3 |
33 | hhm | 10 |
34 | highflux | 1 |
35 | ifn-alpha2 | 2 |
36 | improvement.the | 1 |
37 | induction/maintenance | 4 |
38 | induction/stabilization | 3 |
39 | interferon-alpha/ribavirin | 3 |
40 | ldb-cpr | 6 |
41 | maintainance | 11 |
42 | maintenance | 11,053 |
43 | maintenance/regain | 3 |
44 | mini-prophylactic | 1 |
45 | mono-administration | 3 |
46 | o3pufa-enriched | 1 |
47 | osb4 | 2 |
48 | phasing-out | 2 |
49 | pivoxil/kg/day | 1 |
50 | post-ban | 5 |
51 | post-fa | 4 |
52 | pre-control | 2 |
53 | precarcinogenic | 2 |
54 | pseudorotation | 3 |
55 | recidives | 4 |
56 | regimen.this | 1 |
57 | severity/previous | 1 |
58 | st-analysis | 17 |
59 | suppressibility | 4 |
60 | triers | 2 |
61 | tsh-suppressing | 1 |
62 | tumor-inhibiting | 3 |
63 | ve-100 | 2 |
64 | weight-maintenance | 37 |
65 | » | 2 |
1 | ve-100 | 2 |
2 | group-290 | 1 |
3 | ifn-alpha2 | 2 |
4 | osb4 | 2 |
5 | day-15 | 3 |
6 | cs-137 | 6 |
7 | post-fa | 4 |
8 | cytosorb | 3 |
9 | precarcinogenic | 2 |
10 | mini-prophylactic | 1 |
11 | 70-mg/d | 5 |
12 | o3pufa-enriched | 1 |
13 | 400-mg-bid | 3 |
14 | maintenance | 11,053 |
15 | end-of-maintenance | 2 |
16 | weight-maintenance | 37 |
17 | continuation/maintenance | 6 |
18 | induction/maintenance | 4 |
19 | maintainance | 11 |
20 | flukicide | 2 |
21 | heparin-free | 16 |
22 | improvement.the | 1 |
23 | fev1-decline | 3 |
24 | 28.4-g | 1 |
25 | 6-mg/kg | 2 |
26 | 750mg/kg | 6 |
27 | 0.8-mg | 7 |
28 | tsh-suppressing | 1 |
29 | tumor-inhibiting | 3 |
30 | complications.both | 1 |
31 | hepatic-arterial | 3 |
32 | pre-control | 2 |
33 | hhm | 10 |
34 | post-ban | 5 |
35 | maintenance/regain | 3 |
36 | azythromicin | 1 |
37 | interferon-alpha/ribavirin | 3 |
38 | examination/installation | 1 |
39 | mono-administration | 3 |
40 | cotransplantation | 5 |
41 | pseudorotation | 3 |
42 | continuation | 1,415 |
43 | induction/stabilization | 3 |
44 | follow-up.whether | 1 |
45 | diethylether | 2 |
46 | concealer | 3 |
47 | bronchodialator | 1 |
48 | ldb-cpr | 6 |
49 | exothermicities | 2 |
50 | recidives | 4 |
51 | regimen.this | 1 |
52 | st-analysis | 17 |
53 | 52-weeks | 11 |
54 | every-4-weeks | 4 |
55 | 14-weeks | 7 |
56 | triers | 2 |
57 | severity/previous | 1 |
58 | phasing-out | 2 |
59 | 48iu | 3 |
60 | highflux | 1 |
61 | 4-g/day | 2 |
62 | pivoxil/kg/day | 1 |
63 | 20-mg/day | 6 |
64 | suppressibility | 4 |
65 | » | 2 |